Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Sabry Ayad

Anesthesiology Cleveland, OH Medical Doctor

NPI 1649271800 CMS profile 120214

18101 Lorain Ave, Cleveland, OH 44111

Open in the dashboard

General payments

$427,026

663 records reported · program years 2019–2025

Research payments

$25,078

Paid to them · 11 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$423,893 paid to institutions, not to them · program years 2020–2025

Through program year 2025, Sabry Ayad of Cleveland, OH is reported in the CMS Open Payments database as having received $427,026 across 663 general payments and $25,078 in research payments paid to them. Separately, studies naming them as principal investigator received $423,893 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 99th percentile of Anesthesiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

9 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $55,727 90
2024 General $33,722 47
2023 General $32,666 42
2023 Research $1,953 5
2022 General $34,284 40
2021 General $82,298 115
2021 Research $23,125 6
2020 General $30,402 39
2019 General $157,927 290

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Sabry Ayad
  • Anesthesiology median
  • Middle half of Anesthesiology
  • National median

In program year 2025, general payments to Sabry Ayad were reported at $55,727. Among 18,548 Anesthesiology profiles paid that year, the median was $58 and the middle half received between $26 and $153.

Show as a table
Year Sabry Ayad Anesthesiology median Middle half National median
2019 $157,927 $72 $23–$151 $163
2020 $30,402 $36 $17–$120 $114
2021 $82,298 $49 $21–$135 $132
2022 $34,284 $52 $22–$144 $149
2023 $32,666 $53 $23–$143 $160
2024 $33,722 $55 $25–$150 $164
2025 $55,727 $58 $26–$153 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Pacira Pharmaceuticals Incorporated $174,767 314 payments
  2. Vertex Pharmaceuticals Incorporated $54,013 63 payments
  3. Covidien LP $42,215 40 payments
  4. Heron Therapeutics, Inc. $33,199 37 payments
  5. Trevena, Inc. $26,060 14 payments
  6. Acacia Pharma Inc $22,038 36 payments
  7. Eagle Pharmaceuticals, Inc. $20,552 24 payments
  8. Medtronic, Inc. $19,263 23 payments
  9. Takeda Pharmaceuticals U.S.A., Inc. $10,428 4 payments
  10. Philips Electronics North America Corporation $5,825 6 payments
  11. Other $18,667 102 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $222,040 95 payments
  2. Consulting Fee $90,936 58 payments
  3. Travel and Lodging $65,697 207 payments
  4. Honoraria $35,194 19 payments
  5. Food and Beverage $13,143 283 payments
  6. Education $16 1 payment
Products named General payments · program years 2019–2025
  1. EXPAREL Pain Management $142,306 264 payments
  2. JOURNAVX $41,291 51 payments
  3. BARHEMSYS Post Operative Nausea and Vomiting $37,190 47 payments
  4. Zynrelef $33,152 36 payments
  5. Exparel Pain Management $32,461 50 payments
  6. OLINVYK $26,060 14 payments
  7. Nellcor $24,852 23 payments
  8. BIS $5,379 3 payments
  9. MCGRATH MAC $4,845 3 payments
  10. BARHEMSYS PONV postoperative nausea vomiting $4,390 9 payments
  11. Other $16,209 109 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Trevena, Inc. $22,625 5 payments
  2. Takeda Pharmaceuticals U.S.A., Inc. $1,953 5 payments
  3. US Endoscopy $500 1 payment

Billing to Medicare

Part B · data year 2024 · 40 billing codes

Paid by Medicare

$11,703

Medicare's payments for the services billed

Medicare patients

100

Average age 73

Services billed

112

55 women, 45 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 57%
Ischemic heart disease 40%
Chronic kidney disease 36%
Diabetes 34%
Depression 32%
Atrial fibrillation 31%
Cancer 28%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

3 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Exparel
  • Pacira Pharmaceuticals Incorporated $6,199
$6,199 — —
ULTOMIRIS
  • Alexion Pharmaceuticals, Inc. $1,683
$1,683 — —
APONVIE
  • Heron Therapeutics, Inc. $46
$46 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

674 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Anesthesiology in Ohio

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record